^
Association details:
| Biomarker: | DNMT3A mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | azacitidine (DNA methylation inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Excerpt:
...Acute myeloid leukemia with either Flt-3, TET-2, p53, DNMT3A, or ASXL1 mutation, mutations of genes involved in the chromatin/spliceosome category (EZH2, SRSF2, U2AF1, ZRSR2), BCOR, and RUNX1, as well as MLL rearrangement, EVI1 overexpression in complete morphologic remission; or 3....
Trial ID:
Source:
Title:
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Excerpt:
A total of 113 pts were treated: 73 with decitabine and 40 with azacitidine…On multivariate analysis, age, U2AF1, TP53, and DNMT3A mutations all correlate with poor OS…Mutations had similar effects on OS regardless of HMA used….Low-doses of HMA in pts with lower-risk MDS are safe and can improve outcomes compared to historical data in pts with intermediate or high risk features by the MDA-LRPSS.
DOI:
10.1182/blood-2019-129141
